References
- Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193–201. doi:10.1016/j.ophtha.2013.08.011
- Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121:2247–2254. doi:10.1016/j.ophtha.2014.05.006
- Clark WL, Boyer DS, Heier JS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology. 2016;123:330–336. doi:10.1016/j.ophtha.2015.09.035
- Korobelnik JF, Holz FG, Roider J, et al. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the Phase 3 GALILEO study. Ophthalmology. 2014;121:202–208. doi:10.1016/j.ophtha.2013.08.012
- Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155():429–437.e7. doi:10.1016/j.ajo.2012.09.026
- Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237:185–222. doi:10.1159/000458539
- Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, et al. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2019;242:123–162. doi:10.1159/000502041
- Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144–1167. doi:10.1136/bjophthalmol-2014-305702
- Royal College of Ophthalmology. Ophthalmic Service Guidance. Intravitreal Injection Therapy. London, UK: Royal College of Ophthalmology; 2018.
- Royal College of Ophthalmology. Ophthalmic Service Guidance. Managing an Outbreak of Postoperative Endophthalmitis. London, UK: Royal College of Ophthalmology; 2022.
- Anderson WJ, da Cruz NFS, Lima LH, Emerson GG, Rodrigues EB, Melo GB. Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. Int J Retina Vitr. 2021;7:1–12. doi:10.1186/s40942-021-00307-7
- Cox JT, Eliott D, Sobrin L, Eli I, Winocur E, Sarig R. Inflammatory complications of intravitreal anti-VEGF injections. J Clin Med. 2021;11:10. doi:10.3390/jcm10050981
- Joh NH, Thomas L, Christian TR, et al. Silicone oil particles in prefilled syringes with human monoclonal antibody, representative of real-world drug products, did not increase immunogenicity in in vivo and in vitro model systems. J Pharm Sci. 2020;109:845–853. doi:10.1016/j.xphs.2019.09.026
- European Medicines Agency. Beovu European public assessment report; 2019. Available from: https://www.ema.europa.eu/en/documents/assessment-report/beovu-epar-public-assessment-report_en.pdf. Accessed January 11, 2023.
- Monés J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion–related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128:1050–1059. doi:10.1016/j.ophtha.2020.11.011
- Baumal CR, Spaide RF, Vajzovic L, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127:1345–1359. doi:10.1016/j.ophtha.2020.04.017
- Schmidt-Ott U, Hughes D, Chu K, et al. Differing risks of occlusive retinal vasculitis with concurrent intraocular inflammation among intravitreal antivascular endothelial growth factor therapies. Retina. 2021;41:669–670. doi:10.1097/IAE.0000000000003015
- Bayer. Eylea (aflibercept) summary of product characteristics; 2018. Available from: https://www.ema.europa.eu/documents/product-information/eylea-epar-product-information_en.pdf. Accessed January 3, 2023.
- Bayer. Intravitreal VEGF inhibitor EYLEA® approved as a treatment of neovascular glaucoma (NVG), its fifth indication. Available from: https://moneyworld.jp/discl-pdf/tdnet/2020032548418601GENERAL.pdf. Accessed January 3, 2023.
- Sassalos TM, Paulus YM. Prefilled syringes for intravitreal drug delivery. Clin Ophthalmol. 2019;13:701–706. doi:10.2147/OPTH.S169044
- Souied E, Nghiem-Buffet S, Leteneux C, et al. Ranibizumab prefilled syringes: benefits of reduced syringe preparation times and less complex preparation procedures. Eur J Ophthalmol. 2015;25:529–534. doi:10.5301/ejo.5000629
- Denys P, Miere A, Colantuono D, Jung C, Souied EH. Intravitreal injections during COVID-19 outbreak: protective measures, total duration of care and perceived quality of care in a tertiary retina center. Eur J Ophthalmol. 2022;32:372–376. doi:10.1177/11206721211003488
- Novartis. Post-marketing data in patients with wet AMD and DME. Available from: https://www.brolucizumab.info/post-marketing-data. Accessed January 3, 2023.